Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval, making it the first precision medicine combo for patients with BRCA2-mutated metastatic ...
Incidence of myelodysplastic syndrome in patients treated with PARP inhibitors: A systematic review.
Investigating the role of immunosurveillance by macrophage in supporting therapeutic strategies using CD47 blockade in MDS. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results